Загрузка...
Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?
Individuals <2 years and ≥50 years of age, as well as those with other specific risk factors, are especially vulnerable to invasive pneumococcal disease (IPD). Conjugate vaccines have been developed against encapsulated bacteria such as Streptococcus pneumoniae to provide improved immune response...
Сохранить в:
| Опубликовано в: : | Eur J Clin Microbiol Infect Dis |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Berlin Heidelberg
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4281374/ https://ncbi.nlm.nih.gov/pubmed/25149825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10096-014-2208-6 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|